Table 6 Adverse events in the linezolid and control groups*
Adverse event | Linezolid group (n = 164) | Control group (n = 172) | P value |
|---|---|---|---|
Nausea/vomiting | 20 (12.2) | 23 (13.4) | 0.747 |
Liver injury | 11 (6.7) | 10 (5.8) | 0.735 |
Renal injury | 3 (1.8) | 4 (2.3) | 1.000 |
Anemia | 29 (17.7) | 3 (1.7) | < 0.001 |
Thrombocytopenia | 7 (4.3) | 2 (1.2) | 0.098 |
Leucopenia | 4 (2.4) | 2 (1.2) | 0.439 |
Peripheral neuropathy | 21 (12.8) | 1 (0.6) | < 0.001 |
Optic neuropathy | 4 (2.4) | 0 (0.0) | 0.056 |
Rash | 12 (7.3) | 13 (7.6) | 0.933 |
Skin discoloration (pink to brownish-black) | 73 (44.5) | 91 (62.9) | 0.124 |
Ichthyosis | 30 (18.3) | 44 (25.6) | 0.107 |
Drug-induced fever | 5 (3.0) | 5 (2.9) | 0.939 |
Tinnitus or hearing loss | 4 (2.4) | 3 (4.7) | 0.718 |
QTc prolongation | 11 (6.7) | 14 (8.1) | 0.617 |
Others | 4 (2.4) | 3 (1.7) | 0.718 |